Patents by Inventor Ali Shilatifard

Ali Shilatifard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF NUCLEOTIDE SYNTHESIS INHIBITORS FOR TARGETED THERAPY IN MLL3/4 COMPASS MUTANT CANCER
    Publication number: 20230390297
    Abstract: Disclosed herein are methods and compositions for treating a subject comprising the administration of an effective amount of a nucleotide synthesis inhibitor to a subject in need of treatment for a MLL3/4 COMPASS deficient cancer or a MLL3/4 loss of function mutation.
    Type: Application
    Filed: June 2, 2023
    Publication date: December 7, 2023
    Inventors: Ali Shilatifard, Zibo Zhao
  • Therapeutic targeting of the BAP1 complex in cancer
    Patent number: 11672794
    Abstract: Disclosed are methods for methods, compounds, and compositions for treating cancers characterized by therapeutic targeting of the BAP1 histone H2A deubiquitinase (DUB) complex, otherwise referred to herein as the BAP1 complex. In particular, the methods, compounds, and compositions disclosed herein relate to the use of therapeutic agents that inhibit the biological activity of the BAP1 complex for treating cancers such as myeloid neoplasms.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: June 13, 2023
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Lu Wang, Ali Shilatifard
  • Small molecules for disrupting the super elongation complex and inhibiting transcription elongation for cancer therapy
    Patent number: 11453640
    Abstract: Disclosed are compounds which may be utilized to inhibit transcription by RNA Polymerase II (Pol II), and in particular to disrupt the Super Elongation Complex (SEC). The compounds may be utilized in pharmaceutical compositions and methods for treating diseases and disorders associated with the biological activity of SEC, and in particular, diseases and disorders that are associated with high levels of expression of genes whose expression is SEC-dependent and that promote, support, or otherwise are required for the disease or disorder such as cancers.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: September 27, 2022
    Assignee: Northwestern University
    Inventors: Ali Shilatifard, Kaiwei Liang, Edwin R. Smith, Gary E. Schiltz, Rama K. Mishra, Kristen Stoltz
  • Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors
    Patent number: 11071727
    Abstract: Disclosed are methods and pharmaceutical compositions for treating a cancer in a subject in need thereof, the cancer characterized by proteolytic cleavage by taspase1 of the mixed-lineage leukemia 1 gene product (MLL1), the method comprising administering to the subject a therapeutic agent that inhibits cleavage by taspase1 of MLL1. Suitable therapeutic agents may include agents that inhibit the kinase activity of casein kinase II (CKII). Cancer treated by the disclosed methods and pharmaceutical compositions may include leukemia such as Acute Lymphoblastic Leukemia (ALL) and/or Acute Myeloid Leukemia (AML) and in particular, leukemia characterized by rearrangements in MLL1.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: July 27, 2021
    Assignee: Northwestern University
    Inventors: Ali Shilatifard, Zibo Zhao
  • Therapeutic targeting of SET1B/compass pathway for treating cancers
    Patent number: 11059878
    Abstract: Disclosed are methods for treating Set1/COMPASS-associated cancers characterized by expression of Set1B/COMPASS. The methods typically include administering a therapeutic amount of an inhibitor of the Set1B/COMPASS pathway and/or an agonist for a target that is negatively regulated by the Set1B/COMPASS pathway.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: July 13, 2021
    Assignee: Northwestern University
    Inventors: Ali Shilatifard, Lu Wang
  • SMALL MOLECULES FOR DISRUPTING THE SUPER ELONGATION COMPLEX AND INHIBITING TRANSCRIPTION ELONGATION FOR CANCER THERAPY
    Publication number: 20210094907
    Abstract: Disclosed are compounds which may be utilized to inhibit transcription by RNA Polymerase II (Pol II), and in particular to disrupt the Super Elongation Complex (SEC). The compounds may be utilized in pharmaceutical compositions and methods for treating diseases and disorders associated with the biological activity of SEC, and in particular, diseases and disorders that are associated with high levels of expression of genes whose expression is SEC-dependent and that promote, support, or otherwise are required for the disease or disorder such as cancers.
    Type: Application
    Filed: March 21, 2019
    Publication date: April 1, 2021
    Inventors: Ali Shilatifard, Kaivvei Liang, Edwin R. Smith, Gary E. Schiitz, Rama K. Mishra, Kristen Stoltz
  • THERAPEUTIC TARGETING OF THE BAP1 COMPLEX IN CANCER
    Publication number: 20210060001
    Abstract: Disclosed are methods for methods, compounds, and compositions for treating cancers characterized by therapeutic targeting of the BAP1 histone H2A deubiquitinase (DUB) complex, otherwise referred to herein as the BAP1 complex. In particular, the methods, compounds, and compositions disclosed herein relate to the use of therapeutic agents that inhibit the biological activity of the BAP1 complex for treating cancers such as myeloid neoplasms.
    Type: Application
    Filed: July 17, 2020
    Publication date: March 4, 2021
    Applicant: NORTHWESTERN UNIVERSITY
    Inventors: Lu Wang, Ali Shilatifard
  • THERAPEUTIC TARGETING OF SET1B/COMPASS PATHWAY FOR TREATING CANCERS
    Publication number: 20200223895
    Abstract: Disclosed are methods for treating Set1/COMPASS-associated cancers characterized by expression of Set1B/COMPASS. The methods typically include administering a therapeutic amount of an inhibitor of the Set1B/COMPASS pathway and/or an agonist for a target that is negatively regulated by the Set1B/COMPASS pathway.
    Type: Application
    Filed: March 15, 2019
    Publication date: July 16, 2020
    Applicant: Northwestern University
    Inventors: Ali Shilatifard, Lu Wang
  • Therapeutic targeting of interleukin-1 receptor-associated kinase 4 (IRAK4) in cancers characterized by rearrangements in the mixed lineage leukemia gene (MLL-r)
    Patent number: 10640502
    Abstract: Disclosed are methods for treating cancers associated with rearrangements in the mixed lineage leukemia gene (MLL-r), including MLL-r leukemia. The methods typically include administering a therapeutic amount of one or more therapeutic agents that inhibit the biological activity of one or more members of the interleukin-1 signaling pathway such inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4).
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: May 5, 2020
    Assignee: Northwestern University
    Inventors: Ali Shilatifard, Kaiwei Liang, Edwin Richard Smith, Gary E. Schiltz
  • THERAPEUTIC TARGETING OF PROTEOLYTIC CLEAVAGE OF THE MIXED LINEAGE LEUKEMIA GENE PRODUCT (MLL1) BY TASPASE1 USING KINASE INHIBITORS
    Publication number: 20190231759
    Abstract: Disclosed are methods and pharmaceutical compositions for treating a cancer in a subject in need thereof, the cancer characterized by proteolytic cleavage by taspase1 of the mixed-lineage leukemia 1 gene product (MLL1), the method comprising administering to the subject a therapeutic agent that inhibits cleavage by taspase1 of MLL1. Suitable therapeutic agents may include agents that inhibit the kinase activity of casein kinase II (CKII). Cancer treated by the disclosed methods and pharmaceutical compositions may include leukemia such as Acute Lymphoblastic Leukemia (ALL) and/or Acute Myeloid Leukemia (AML) and in particular, leukemia characterized by rearrangements in MLL1.
    Type: Application
    Filed: January 25, 2019
    Publication date: August 1, 2019
    Applicant: Northwestern University
    Inventors: Ali Shilatifard, Zibo Zhao
  • Therapeutic targeting of SET1B/compass pathway for treating cancers
    Patent number: 10308698
    Abstract: Disclosed are methods for treating Set1/COMPASS-associated cancers characterized by expression of Set1B/COMPASS. The methods typically include administering a therapeutic amount of an inhibitor of the Set1B/COMPASS pathway and/or an agonist for a target that is negatively regulated by the Set1B/COMPASS pathway.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: June 4, 2019
    Assignee: Northwestern University
    Inventors: Ali Shilatifard, Lu Wang
  • THERAPEUTIC TARGETING OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 (IRAK4) IN CANCERS CHARACTERIZED BY REARRANGEMENTS IN THE MIXED LINEAGE LEUKEMIA GENE (MLL-r)
    Publication number: 20180319795
    Abstract: Disclosed are methods for treating cancers associated with rearrangements in the mixed lineage leukemia gene (MLL-r), including MLL-r leukemia. The methods typically include administering a therapeutic amount of one or more therapeutic agents that inhibit the biological activity of one or more members of the interleukin-1 signaling pathway such inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4).
    Type: Application
    Filed: July 9, 2018
    Publication date: November 8, 2018
    Applicant: Northwestern University
    Inventors: Ali Shilatifard, Kaiwei Liang, Edwin Richard Smith
  • Therapeutic targeting of the interleukin 1 receptor-associated kinase 4 (IRAK4) in leukemias characterized by rearrangements in the mixed lineage leukemia gene (MLL-r)
    Patent number: 10059708
    Abstract: Disclosed are methods for treating cancers associated with rearrangements in the mixed lineage leukemia gene (MLL-r), including MLL-r leukemia. The methods typically include administering a therapeutic amount of one or more therapeutic agents that inhibit the biological activity of one or more members of the interleukin-1 signaling pathway such inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4).
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: August 28, 2018
    Assignee: Northwestern University
    Inventors: Ali Shilatifard, Kaiwei Liang, Edwin Richard Smith
  • THERAPEUTIC TARGETING OF SET1B/COMPASS PATHWAY FOR TREATING CANCERS
    Publication number: 20180009870
    Abstract: Disclosed are methods for treating Set1/COMPASS-associated cancers characterized by expression of Set1B/COMPASS. The methods typically include administering a therapeutic amount of an inhibitor of the Set1B/COMPASS pathway and/or an agonist for a target that is negatively regulated by the Set1B/COMPASS pathway.
    Type: Application
    Filed: July 10, 2017
    Publication date: January 11, 2018
    Applicant: Northwestern University
    Inventors: Ali Shilatifard, Lu Wang
  • THERAPEUTIC TARGETING OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 (IRAK4) IN CANCERS CHARACTERIZED BY REARRANGEMENTS IN THE MIXED LINEAGE LEUKEMIA GENE (MLL-r)
    Publication number: 20170305901
    Abstract: Disclosed are methods for treating cancers associated with rearrangements in the mixed lineage leukemia gene (MLL-r), including MLL-r leukemia. The methods typically include administering a therapeutic amount of one or more therapeutic agents that inhibit the biological activity of one or more members of the interleukin-1 signaling pathway such inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4).
    Type: Application
    Filed: April 26, 2017
    Publication date: October 26, 2017
    Applicant: Northwestern University
    Inventors: Ali Shilatifard, Kaiwei Liang, Edwin Richard Smith
  • ELL2, a new member of an ELL family of RNA polymerase II elongation factors
    Publication number: 20020132329
    Abstract: ELL2 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing ELL2 polypeptides and polynucleotides in the design of protocols for the treatment of neoplastic disorders, among others and diagnostic assays for such conditions.
    Type: Application
    Filed: December 28, 2001
    Publication date: September 19, 2002
    Applicant: Human Genome Sciences, Inc.
    Inventors: D. Roxanne Duan, Ali Shilatifard, Joan W. Conaway, Ronald C. Conaway
  • ELL2, a new member of an ELL family of RNA polymerase II elongation factors
    Patent number: 6379923
    Abstract: ELL2 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing ELL2 polypeptides and polynucleotides in the design of protocols for the treatment of neoplastic disorders, among others and diagnostic assays for such conditions.
    Type: Grant
    Filed: July 29, 1999
    Date of Patent: April 30, 2002
    Assignees: Human Genome Sciences, Inc., Oklahoma Medical Research Foundation
    Inventors: D. Roxanne Duan, Ali Shilatifard, Joan W. Conaway, Ronald C. Conaway
  • ELL2, a new member of an ELL family of RNA polymerase II elongation factors
    Patent number: 6008018
    Abstract: ELL2 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing ELL2 polypeptides and polynucleotides in the design of protocols for the treatment of neoplastic disorders, among others and diagnostic assays for such conditions.
    Type: Grant
    Filed: February 19, 1998
    Date of Patent: December 28, 1999
    Assignees: Human Genome Sciences, Inc., Oklahoma Medical Research Foundation
    Inventors: D. Roxanne Duan, Ali Shilatifard, Joan W. Conaway, Ronald C. Conway